(3) Each survey shall be conducted in a manner 
that ensures the anonymity of the individual being 
surveyed. 
(d) MATTERS SURVEYED.— 
(1) VETERANS.—The survey described in sub-
section (c)(1) shall cover the following subjects: 
(A) The current medicinal cannabis use by 
the veteran, or the intent or desire by the vet-
eran to use medicinal cannabis, and the reasons 
for such use, intent, or desire. 
(B) The conditions, symptoms, or both, 
that the veteran uses cannabis to treat. 
(C) The types of cannabis and cannabis 
products used by the veteran, including with re-
spect to— 
(i) tetrahydrocannabinol or cannabidi-
ol content; 
(ii) indica, sativa, mixes, or hybrids; 
and 
(iii) flower, oils, hash or kief, con-
centrates (wax, shatter, budder), edibles, 
drinks, tinctures, and topical ointments. 
(D) Other medications taken by the vet-
eran concurrently with cannabis and any medi-
VerDate Sep 11 2014 
00:27 May 22, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2676.IH
H2676
SSpencer on DSKBBXCHB2PROD with BILLS
cations the veteran stopped using because of 
the use of cannabis. 
(E) How the veteran is self-administering 
medicinal cannabis, including— 
(i) the method; 
(ii) the typical times each day the vet-
eran self-administers; 
(iii) the frequency of different prod-
ucts per day and for what condition, symp-
tom, or both; and 
(iv) the amounts per product. 
(F) The ratings and descriptions of the ef-
fectiveness of using cannabis to treat condi-
tions, symptoms, or both. 
(G) Any experiences with side effects. 
(H) The number of different cannabis 
products tried before settling on the current 
product. 
(I) The typical source of medical cannabis 
(such as a single dispensary, multiple dispensa-
ries, mail order, or other source), the typical 
purchase frequency, and the typical amount 
purchased. 
(J) The sources of information the veteran 
uses for products and dosages. 
VerDate Sep 11 2014 
00:27 May 22, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2676.IH
H2676
SSpencer on DSKBBXCHB2PROD with BILLS
(K) Factors that influence the choice of 
the veteran for using a chosen product (such as 
with respect to the levels of tetrahydrocannabi-
nol or cannabidiol content, cost, availability, 
consistency, or strain). 
(L) Any other matters determined appro-
priate. 
(2) HEALTH CARE PROVIDERS.—The survey de-
scribed in subsection (c)(2) shall cover the following 
subjects: 
(A) A description of the experience of the 
health care provider with respect to patients 
using medicinal cannabis. 
(B) A description by the health care pro-
vider of how medicinal cannabis is changing pa-
tients. 
(C) A description of how treatment plans 
have been modified after a veteran discloses 
using cannabis. 
(D) Any documentation of the products, 
dosages, or frequency of such cannabis use in 
the medical records of the veteran. 
(E) Reporting of adverse events. 
(F) The sources of information used by the 
health care provider with respect to cannabis 
VerDate Sep 11 2014 
00:27 May 22, 2019
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2676.IH
H2676
SSpencer on DSKBBXCHB2PROD with BILLS
products and the medical effectiveness of can-
nabis. 
(G) Any other matters determined appro-
priate. 
(e) REPORT.—Not later than one year after the date 
of the enactment of this Act, the Secretary shall submit 
to the Committees on Veterans’ Affairs of the Senate and 
the House of Representatives a report on the results of 
the surveys conducted under this section. 
Æ 
VerDate Sep 11 2014 
00:27 May 22, 2019
Jkt 089200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H2676.IH
H2676
SSpencer on DSKBBXCHB2PROD with BILLS